BNGO BNGO
Company Profile ↓Company Overview
BNGO (BNGO) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 14.7% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $28.51M (-7.4% YoY); net profit $-26.39M.
- Trailing 12 Months Year-on-year growth — revenue -7.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 14.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 14.72% |
| 1 Year: | -7.37% |
Stock Price Performance
| 1 Year: | -64.57% |
| 6 Months: | -10.83% |
| 3 Months: | -13.71% |
| 1 Month: | -6.14% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.18 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 14.7% over 5 years.
CONS
- Trading 78.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 2.74M | - | 1.77M | 3.39M | 2.83M | 4.01M | 1.85M | 2.17M | 3.31M | 2.79M | 1.14M | 1.18M | 2.20M | 3.17M | 3.86M | 4.66M | 5.70M | 6.67M | 7.22M | 7.42M | 8.66M | 9.32M | 8.77M | 7.77M | 6.07M | 6.46M | 6.73M | 7.37M | 6.69M |
| Operating Income | - | - | -5.03M | - | -4.34M | -4.01M | -5.97M | - | -6.18M | -6.84M | -5.68M | - | -9.76M | -7.43M | -10.23M | -11.16M | -16.48M | -20.68M | -29.94M | -32.08M | -32.15M | -37.84M | -39.24M | -113.21M | -31.12M | -17.02M | -43.90M | -8.46M | -7.80M | -8.54M | -7.90M |
| Net Income | 5.69M | 6.67M | 5.09M | 5.92M | -3.85M | -3.31M | -4.93M | -6.41M | -7.85M | -7.67M | -6.40M | -7.90M | -10.51M | -8.07M | -10.79M | -9.95M | -18.79M | -20.75M | -29.95M | -32.16M | -31.81M | -37.12M | -38.91M | -112.57M | -31.42M | -16.22M | -44.25M | -3.10M | -6.86M | -8.50M | -8.30M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.09 | -0.08 | -0.04 | -0.07 | -0.07 | -0.11 | -1.13 | -1.10 | -1.23 | -1.24 | -3.22 | -35.75 | -14.41 | -30.92 | -1.15 | -1.99 | -1.59 | -0.76 |
| R&D Expense | - | - | 2.97M | - | 2.37M | 2.10M | 2.51M | - | 2.10M | 2.41M | 2.17M | - | 2.67M | 2.40M | 2.30M | 2.68M | 4.09M | 6.50M | 10.53M | 11.77M | 12.74M | 13.94M | 14.61M | 13.79M | 9.78M | 6.83M | 4.72M | 2.37M | 2.93M | 2.84M | 3.14M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.51M | 12.00M | 10.13M | 8.50M | 17.98M | 27.80M | 36.12M | 30.78M | 28.51M |
| Operating Income | -23.22M | -20.42M | -25.87M | -38.55M | -77.10M | -131.70M | -215.25M | -103.98M | -33.34M |
| Net Income | -23.37M | -18.50M | -29.82M | -41.11M | -72.44M | -132.60M | -232.49M | -112.02M | -26.39M |
| Diluted EPS | - | - | - | - | -0.26 | -4.58 | -408.60 | -88.13 | -4.85 |
| R&D Expense | 12.01M | 9.48M | 9.08M | 10.26M | 22.48M | 49.05M | 54.03M | 24.80M | 11.37M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 10.15M | 24.80M | 30.21M | 60.45M | 377.10M | 307.50M | 214.40M | 76.67M | 73.58M |
| Total Equity | -27.26M | -50.23M | 10.14M | 3.61M | 35.08M | 337.12M | 249.40M | 96.16M | 35.38M | 44.42M |
| Cash & Equivalents | - | 1.02M | 16.52M | 17.31M | 38.45M | 24.57M | 5.09M | 17.95M | 9.17M | 2.99M |
| Long Term Debt | - | 0 | 9.03M | 0 | 16.32M | 0 | - | - | - | - |
| Total Liabilities | - | 17.36M | 14.67M | 26.59M | 25.37M | 39.98M | 58.10M | 118.25M | 41.30M | 29.16M |
| Current Liabilities | - | 16.65M | 4.52M | 26.37M | 8.95M | 21.84M | 35.88M | 100.03M | 37.34M | 22.94M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -20.82M | -19.94M | -29.53M | -38.31M | -71.93M | -124.82M | -125.18M | -68.92M | -16.34M |
| Investing Cash Flow | -1.02M | -331.72K | -61.06K | -2.45M | -278.06M | 82.77M | 24.16M | 73.84M | -12.75M |
| Financing Cash Flow | 17.61M | 35.78M | 30.38M | 61.90M | 336.11M | 23.01M | 113.81M | -13.69M | 24.04M |
| Capital Expenditure | -1.02M | -331.72K | -61.06K | -0 | - | - | - | - | - |
| Free Cash Flow | -21.84M | -20.28M | -29.59M | -38.31M | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -244.3% | -170.1% | -255.4% | -453.4% | -428.8% | -473.7% | -596.0% | -337.9% | -116.9% |
| Net Margin % | -245.8% | -154.1% | -294.3% | -483.4% | -402.8% | -476.9% | -643.7% | -364.0% | -92.6% |
| ROE % | 46.5% | -182.5% | -825.2% | -117.2% | -21.5% | -53.2% | -241.8% | -316.7% | -59.4% |
| ROCE % | 356.8% | -100.7% | -673.7% | -74.8% | -21.7% | -48.5% | -188.2% | -264.4% | -65.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BNGO
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQbFl4VzE3WkVUY1ZzUnZFV0ZrdnlDVUdoaXZLZEhOb2V6UVdSVjVwRDZYYTRmdUJKb1Y0SW9OaW16dm13ZThteGJaWjJpUEJSMkZSSnBhRTgyOGstdHlwbFhvYUl2eDRQYWhJV2lBUW4xQ0ZxaU9xZl9Sa3JEU2d0dGY4a3JObnhGV0pQX3…
Bionano Genomics (BNGO) CSO reports holding 63 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQM1JOX0t4d1BOVXlLZW1NOUFoaTlwVGFBYlpEYjF4Y21EdVJpVm1BTWJBaDA2M0Z4Wm5vV3lFb2RYcEJUNU5yTDJhWVo1aUdJc1hDdmZiaW1SaV9CZG1kbkZaRG1RanNBNllhekJCYzVqS05TWFNsMkIzZXhKa3hkcG5HQkdRMUx1LWlxNH…
Bionano Genomics, Inc. Revenue Breakdown – NASDAQ:BNGO - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE82M1VKSVhEU0RlNXpqaENHcUdiU3ZNMnJaOWhJZWJWeXZRV2FrVERuTVhRc2RzM29zVjJKUXBFNUNsNmJoeG1FV3JaOEZiVGpfbXpBTVRCNDhHQWZ4c0hFbzJyTWEyMGxxTmdkbFp3b0VwTk45Z2N3?oc=5" target="_blank">Bionano…
BIONANO GENOMICS ($BNGO) Releases Q1 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOQ2M0dEFiRW1oM2x6cmUyQW1Yc0tZQVJlbThIMGsxZkpnQTI5RFN1R3VkdUVoV1JtWlFCcWFDVndIb3QxY3RXWElXUzVNZ0d4UzlTWkwxaU1wc200VEhFT2M2VnhGdXFROVIyNnFYNk50a3dJNnkwVzFTaWo0dXY5a2tNbWV2aksyQlJBS3…
BNGO|Bionano Genomics Inc|Price:1.070|Chg%:+0.010 - TradingKey
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTFBHMkxQNlZ1b1puN1lkd0RlejdZY3JJQXg4aHRJZ2FVeVRmbld5a08yRmROMGUxamdKUXdKM2tIRjJYZjYxTmVuTXhlYkt0S0lPaVBZNnJrMG5Hdw?oc=5" target="_blank">BNGO|Bionano Genomics Inc|Price:1.070|Chg%:+0…
Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Revenues - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxQSmhxWFc4QXNvSDBWOWNyakoweDhTZXNIUWhZbUZtSWFtaDZwaU9TeGN2QXpoYUhJb01VcndORDB1TS1qRkZpZ3ZYZGhYQmVHQjdld0NKZldYSjRvMXd1UFItVzNSUU1lX0t2X21tUGx3VTZWdmdXdFFweVl6eElPUHpTMnk3bDZBbnJMaz…
BNGO — Frequently Asked Questions
What is the current share price of BNGO?
As of 2026-08-05 17:25 PDT, BNGO trades at $1.07 on NASDAQ/NYSE. Its 52-week range is $1.06 to $4.92.
What is the P/E ratio of BNGO?
BNGO trades at a trailing price-to-earnings (P/E) ratio of -0.22.
What is the return on equity (ROE) of BNGO?
BNGO has a return on equity (ROE) of -59.42%. Its return on capital employed (ROCE) is -65.83%.
Is BNGO a good stock to buy?
This page provides a data-driven analysis of BNGO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.